[1]
Freiman D. The structure of thrombi in Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 2nd ed. 1987.
[2]
Fuster V, Bhatt DL, Califf RM, et al. Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation 2012; 126(13): 1645-62.
[3]
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.
[4]
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361(24): 2342-52.
[5]
Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62(24): 2261-73.
[6]
Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36(27): 1762-71.
[7]
Doundoulakis I, Antza C. Karvounis Haralambos, Giannakoulas G. Non-Vitamin K Antagonist Oral Anticoagulants in acute venus thromboembolism: An overview of systematic reviews. Curr Pharm Des 2020; 26(23): 2686-91.
[8]
Papakonstantinou PE, Tsioufis C, Konstantinidis D, Iliakis P, Leontsinis I, Tousoulis D. Anticoagulation in Deep Venous Thrombosis: Current Trendsin the Era of Non- Vitamin K Antagonists Oral Abticoaguants. Curr Pharm Des 2020; 26(23): 2692-702.
[9]
Antoniou C-K, Manolakou P, Arsenos P, Dilaveris P, Gatzoulis K, Tousoulis D. Antithrombotic treatment after atrial fibrillation ablation. Curr Pharm Des 2020; 26(23): 2703-14.
[10]
Saberwal B, Ioannou A, Lim WY, et al. Antithrombotic therapy in patients with recent stroke and atrial fibrillation. Curr Pharm Des 2020; 26(23): 2715-24.
[11]
Papanikolaou P, Antonopoulos AS, Mastorakou I, et al. Antithrombotic therapy in carotid artery disease. Curr Pharm Des 2020; 26(23): 2725-34.
[12]
Chrysohoou C, Magkas N, Antoniou C-K, Manolakou P, Laina A, Tousoulis D. The role of antithrombotic therapy in heart failure. Curr Pharm Des 2020; 26(23): 2735-61.
[13]
Vogiatzi G, Pantazis A, Tousoulis D. Antithrombotic treatment in cardiomyopathies. Curr Pharm Des 2020; 26(23): 2762-8.
[14]
Drakopoulou M, Soulaidopoulos S, Stathogiannis K, et al. Antiplatelet and antithrombotic therapy after patent foramen oval and atrial septal defect closure. Curr Pharm Des 2020; 26(23): 2769-79.
[15]
Siasos G, Skotsimara G, Oikonomou E, et al. Antithrombotic treatment in diabetes mellitus: A Review of the literature about Antiplatelet and Anticoagulation strategies used for diabetic patients in primary and secondary prevention. Curr Pharm Des 2020; 26(23): 2780-8.
[16]
Drakopoulou M, Soulaidopoulos S, Oikonomou G, et al. Novel prespective for antithrombotic therapy in TAVI. Curr Pharm Des 2020; 26(23): 2789-803.
[17]
Kim V, J. Spandorfer. Epidemiology of venous thromboembolic disease. Emerg Med Clin North Am 2001; 19(4): 839-59.
[18]
Murin S, PS. Romano,, RH White. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002; 88(3): 407-14.
[19]
Lefebvre P, Laliberté F, Nutescu EA, et al. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm 2012; 18(5): 363-74.
